(Q37974894)

26 August 2017

Targeted therapies for renal cell carcinoma: review of adverse event management strategies (English)

1 reference

26 August 2017

1 reference

3

Caroline Robert

0 references

Bernard Escudier

8

object named as

Bernard Escudier

1 reference

26 August 2017

Tim Eisen

1

1 reference

26 August 2017

Cora N Sternberg

2

1 reference

26 August 2017

Peter Mulders

4

1 reference

26 August 2017

Lynda Pyle

5

1 reference

26 August 2017

Stephan Zbinden

6

1 reference

26 August 2017

Hassan Izzedine

7

1 reference

26 August 2017

language of work or name

English

0 references

publication date

10 January 2012

1 reference

Journal of the National Cancer Institute

26 August 2017

1 reference

26 August 2017

104

1 reference

26 August 2017

2

1 reference

26 August 2017

93-113

1 reference

Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).

26 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Dermatologic symptoms associated with the multikinase inhibitor sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Sorafenib: a promising new targeted therapy for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Tolerability of first-line therapy for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Managing side effects of angiogenesis inhibitors in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Keratoacanthomas associated with sorafenib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Pain management, supportive and palliative care in patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Managing adverse events in the use of bevacizumab and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Management of bevacizumab-associated bowel perforation: a case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Home blood-pressure monitoring in patients receiving sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Chemotherapy agents and hypertension: a focus on angiogenesis blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Thrombosis associated with angiogenesis inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

RAF inhibition and induction of cutaneous squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Chemotherapy induced diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

The assessment and management of cancer treatment-related diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Quantifying the impact of standardized assessment and symptom management tools on symptoms associated with cancer-induced anorexia cachexia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Medroxyprogesterone acetate in the management of cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Anorexia-cachexia syndrome: a systematic review of the role of dietary polyunsaturated Fatty acids in the management of symptoms, survival, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

2007 Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Cardiovascular toxicity caused by cancer treatment: strategies for early detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Nursing considerations of bevacizumab use in multiple tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Incidence of brain metastases in renal cell carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Thrombotic events in patients with cancer receiving antiangiogenesis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR511

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJR511

1 reference

release_c5s4siysxbhuza5uhemp67khoy

26 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/c5s4siysxbhuza5uhemp67khoy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference